1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Diagnosis of Latent Tuberculosis Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • Authors: Alfred A. Lardizabal1, Lee B. Reichman2
  • Editor: David Schlossberg3
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: New Jersey Medical School Global Tuberculosis Institute, Rutgers University, Newark, NJ 07103; 2: New Jersey Medical School Global Tuberculosis Institute, Rutgers University, Newark, NJ 07103; 3: Philadelphia Health Department, Philadelphia, PA
    • Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0019-2016
  • Received 03 October 2016 Accepted 13 October 2016 Published 10 February 2017
  • Alfred A. Lardizabal, [email protected]
image of Diagnosis of Latent Tuberculosis Infection
    Preview this microbiology spectrum article:
    Preview Magnify
    Zoom in
    Zoomout

    Diagnosis of Latent Tuberculosis Infection, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/5/1/TNMI7-0019-2016-1.gif /docserver/preview/fulltext/microbiolspec/5/1/TNMI7-0019-2016-2.gif

  • Abstract:

    For 2015, tuberculosis (TB) incidence in the United States has plateaued at 3.0 per 100,000. This remains the lowest case rate since recording started. On the global level, although the TB epidemic is larger than previously estimated, TB deaths and incidence rate continue to fall. For both low and high incidence countries, accelerating the decline in TB incidence towards elimination goals requires that more emphasis be placed on strengthening systems for detection and treatment of latent TB infection (LTBI) in addition to improving TB care globally. Here, we review the tuberculin skin test and gamma interferon release assays currently available for the detection of LTBI.

  • Citation: Lardizabal A, Reichman L. 2017. Diagnosis of Latent Tuberculosis Infection. Microbiol Spectrum 5(1):TNMI7-0019-2016. doi:10.1128/microbiolspec.TNMI7-0019-2016.

References

1. Salinas JL, Mindra G, Haddad MB, Pratt R, Price SF, Langer AJ. 2016. Leveling of tuberculosis incidence—United States, 2013–2015. MMWR Morb Mortal Wkly Rep 65:273–278. [PubMed]
2. Styblo K. 1980. Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 20:1–63. [PubMed]
3. Orme IM, Cooper AM. 1999. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 20:307–312. [PubMed]
4. Edwards PQ. 1972. Tuberculin negative? N Engl J Med 286:373–374. [PubMed]
5. American Thoracic Society. 1981. American Thoracic Society. Diagnostic standards and classification of tuberculosis and other mycobacterial diseases (14th edition). Am Rev Respir Dis 123:343–358.
6. Edwards LB, Comstock GW, Palmer CE. 1968. Contributions of northern populations to the understanding of tuberculin sensitivity. Arch Environ Health 17:507–516. [PubMed]
7. American Lung Association. 1974. The Tuberculin Skin Test: Supplement to Diagnostic Standards and Classification of Tuberculosis and Other Mycobacterial Diseases. American Lung Association, Washington, DC.
8. Palmer CE, Edwards LB, Hopwood L, Edwards PQ. 1959. Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity. J Pediatr 55:413–429. [PubMed]
9. American Thoracic Society. 1981. The tuberculin skin test. Am Rev Respir Dis 124:356–363.
10. Reichman LB, O’Day R. 1978. Tuberculous infection in a large urban population. Am Rev Respir Dis 117:705–712. [PubMed]
11. American Thoracic Society. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recommend Rep 49(RR-6) :1–51. [PubMed]
12. Menzies R, Vissandjee B. 1992. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 145:621–625. [PubMed]
13. Snider DE, Jr. 1985. Bacille Calmette-Guérin vaccinations and tuberculin skin tests. JAMA 253:3438–3439. [PubMed]
14. Centers for Disease Control and Prevention. 2000. Core Curriculum on Tuberculosis, 4th ed. US Government Printing Office, Washington, DC.
15. Reichman LB, O’Day R. 1977. The influence of a history of a previous test on the prevalence and size of reactions to tuberculin. Am Rev Respir Dis 115:737–741. [PubMed]
16. Thompson NJ, Glassroth JL, Snider DE, Jr, Farer LS. 1979. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 119:587–597. [PubMed]
17. American Thoracic Society. 1992. Control of tuberculosis in the United States. Am Rev Respir Dis 146:1623–1633. [PubMed]
18. Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW, Epling JW, Jr, García FA, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP, US Preventive Services Task Force. 2016. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. JAMA 316:962–969. [PubMed]
19. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. 2004. Comparison of a new specific blood test and the skin test in tuberculosis contacts. Am J Respir Crit Care Med 170:65–69. [PubMed]
20. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, Iademarco MF, Rothel JS. 2001. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286:1740–1747. [PubMed]
21. Streeton JA, Desem N, Jones SL. 1998. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 2:443–450. [PubMed]
22. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A. 2003. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361:1168–1173.
23. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Otu JK, Corrah T, Adegbola RA, McAdam KP. 2004. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 38:966–973. [PubMed]
24. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WHH, Latif M, Pasvol G, Hill AV. 2001. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357:2017–2021.
25. Richeldi L, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, Fabbri LM, Lalvani A. 2004. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 170:288–295. [PubMed]
26. Pai M, Zwerling A, Menzies D. 2008. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177–184. [PubMed]
27. Diel R, Loddenkemper R, Nienhaus A. 2010. Evidence-based comparison of commercial interferon-γ release assays for detecting active TB. Chest 137:952–968. [PubMed]
28. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. 2008. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177:1164–1170. [PubMed]
29. Mazurek GH, Villarino ME, Centers for Disease Control and Prevention. 2003. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Recommend Rep 52(RR02) :15–18. [PubMed]
30. Centers for Disease Control and Prevention. 1995. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recommend Rep 44(RR-11) :19–34. [PubMed]
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016
2017-02-10
2019-08-22

Abstract:

For 2015, tuberculosis (TB) incidence in the United States has plateaued at 3.0 per 100,000. This remains the lowest case rate since recording started. On the global level, although the TB epidemic is larger than previously estimated, TB deaths and incidence rate continue to fall. For both low and high incidence countries, accelerating the decline in TB incidence towards elimination goals requires that more emphasis be placed on strengthening systems for detection and treatment of latent TB infection (LTBI) in addition to improving TB care globally. Here, we review the tuberculin skin test and gamma interferon release assays currently available for the detection of LTBI.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Diagnosis of Latent Tuberculosis Infection
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-1,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-1,properties={foaf_givenname=Alfred A., foaf_name=Alfred A. Lardizabal, foaf_surname=Lardizabal, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-2,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-2,properties={foaf_givenname=Lee B., foaf_name=Lee B. Reichman, foaf_surname=Reichman, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-aff2]]}]]
Citation: Lardizabal A, Reichman L. 2017. Diagnosis of latent tuberculosis infection. microbiolspec 5(1): doi:10.1128/microbiolspec.TNMI7-0019-2016
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016.fig1
FIGURE 1
Distribution of reactions to 5 TU of PPD among Alaskans tested in 1962. Reprinted with permission from ( 6 ).
microbiolspec/5/1/TNMI7-0019-2016-fig1_thmb.gif
microbiolspec/5/1/TNMI7-0019-2016-fig1.gif
Image of FIGURE 1
FIGURE 1

Distribution of reactions to 5 TU of PPD among Alaskans tested in 1962. Reprinted with permission from ( 6 ).

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0019-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016.fig2
FIGURE 2
Distribution of reactions to 5 TU of PPD among white Navy recruits from the state of Georgia, with estimate of proportion infected with . Reprinted with permission from ( 7 ).
microbiolspec/5/1/TNMI7-0019-2016-fig2_thmb.gif
microbiolspec/5/1/TNMI7-0019-2016-fig2.gif
Image of FIGURE 2
FIGURE 2

Distribution of reactions to 5 TU of PPD among white Navy recruits from the state of Georgia, with estimate of proportion infected with . Reprinted with permission from ( 7 ).

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0019-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016.fig3
FIGURE 3
Schema of probable distribution of reactors to 5 TU of PPD in the New York City metropolitan area.
microbiolspec/5/1/TNMI7-0019-2016-fig3_thmb.gif
microbiolspec/5/1/TNMI7-0019-2016-fig3.gif
Image of FIGURE 3
FIGURE 3

Schema of probable distribution of reactors to 5 TU of PPD in the New York City metropolitan area.

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0019-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016.fig4
FIGURE 4
Schematic representation of three booster effect possibilities. (See text for discussion.)
microbiolspec/5/1/TNMI7-0019-2016-fig4_thmb.gif
microbiolspec/5/1/TNMI7-0019-2016-fig4.gif
Image of FIGURE 4
FIGURE 4

Schematic representation of three booster effect possibilities. (See text for discussion.)

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0019-2016
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Diagnosis of Latent Tuberculosis Infection
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-1,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-1,properties={foaf_givenname=Alfred A., foaf_name=Alfred A. Lardizabal, foaf_surname=Lardizabal, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-2,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-2,properties={foaf_givenname=Lee B., foaf_name=Lee B. Reichman, foaf_surname=Reichman, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016-aff2]]}]]
Citation: Lardizabal A, Reichman L. 2017. Diagnosis of latent tuberculosis infection. microbiolspec 5(1): doi:10.1128/microbiolspec.TNMI7-0019-2016
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0019-2016.T1
TABLE 1
Criteria for tuberculin positivity, by risk group
Generic image for table
TABLE 1

Criteria for tuberculin positivity, by risk group

Source: microbiolspec February 2017 vol. 5 no. 1 doi:10.1128/microbiolspec.TNMI7-0019-2016

Supplemental Material

No supplementary material available for this content.

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error